AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

DFTX · NASDAQ · Biotechnology

Definium Therapeutics (DFTX)

Develops lysergide and R(-)-MDMA drug candidates for anxiety, depression and autism.

$40.00

After hours−0.33 (−0.82%)

At close$40.33(+2.67%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Cost of revenue	0	0	1	0	0	0	0	0	0	0	0	0
Gross profit	0	0	−1	0	0	0	0	0	0	0	0	0
	22	22	22	24	25	32	32	41	46	48	59	75
Research & development	13	12	11	15	17	22	23	30	31	34	41	49
	8	11	10	10	8	11	9	11	15	14	18	26
General & administrative	8	11	10	10	8	11	9	11	15	14	18	26
Operating income	−22	−22	−22	−24	−25	−32	−32	−41	−46	−48	−59	−75
	4	−2	−32	19	11	−2	9	−2	−22	−3	−18	−84
Interest income	1	1	2	3	4	3	2	3	2	3	3	4
Interest expense	0	0	0	0	1	1	1	2	1	10	1	1
Other non-operating income	−4	2	32	−19	−12	2	−9	0	20	−7	17	83
Income before tax	−18	−24	−54	−6	−14	−35	−23	−43	−67	−50	−77	−159
Net income from continuing operations	−18	−24	−54	−6	−14	−35	−23	−43	−67	−50	−77	−159
Net income	−18	−24	−54	−6	−14	−35	−23	−43	−67	−50	−77	−159
EPS, basic	−$0.45	−$0.59	−$1.14	−$0.08	−$0.18	−$0.41	−$0.27	−$0.50	−$0.78	−$0.51	−$0.71	−$1.44
EPS, diluted	−$0.45	−$0.59	−$1.14	−$0.08	−$0.17	−$0.41	−$0.35	−$0.50	−$0.78	−$0.50	−$0.71	−$1.44
Weighted average shares, basic	40	40	48	72	78	84	85	85	86	89	109	111
Weighted average shares, diluted	40	40	48	72	80	84	87	85	86	89	109	111
EBITDA	−17	−23	−53	−5	−1	−33	−23	−40	−66	−41	−75	−158
Depreciation & amortization	1	1	1	0	12	1	0	0	0	0	1	0
EBIT	−18	−24	−54	−5	−13	−34	−23	−40	−66	−41	−76	−158